1. Scrip
  2. >>Leadership

Pharma Not-For-Profit Projects Can Only Improve Reputation

Increased Focus on Planet, Not Just Pills

 
• By Kevin Grogan

Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.

Paul Hudson
Sanofi CEO Paul Hudson taking social responsibility seriously • Source: Sanofi

Big pharma’s reputation with the public seems to have risen given its leading role in tackling the pandemic but beyond COVID-19, drugmakers will be hoping their efforts in tackling pressing issues such as healthcare inequalities and climate change can build on that goodwill.

The latest example of walking the walk in terms of corporate social responsibility (CSR) is Sanofi‘s decision to form...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.